Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 3/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.47 |
| ▸ | PLAT | P00750 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4756703 | 0.84 | DPP4 (0.50) | F10GAAKMT2AF2KLKB1 | |
| SCHEMBL3172775 | 0.84 | DPP4 (0.50) | F10GAAKMT2AF2KLKB1 | |
| SCHEMBL24322499 | 0.84 | DPP4 (0.50) | F10GAAKMT2AF2KLKB1 | |
| Hydrochloric Acid SCHEMBL3166514 | 0.83 | DPP4 (0.49) | F10GAAKMT2AF2KLKB1 | |
| Hydrochloric Acid SCHEMBL3166507 | 0.83 | DPP4 (0.49) | F10GAAKMT2AF2KLKB1 | |
| SCHEMBL24324150 | 0.82 | F10 (0.56) | F10F2KLKB1PLAT | |
| SCHEMBL4495030 | 0.80 | F10 (0.57) | F10F2KLKB1PLAT | |
| SCHEMBL24322372 | 0.77 | F10 (0.54) | F10F2KLKB1PLAT | |
| SCHEMBL10958361 | 0.76 | ACE (0.49) | KMT2A | |
| SCHEMBL24322700 | 0.76 | F10 (0.53) | F10F2KLKB1PLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009172-A1 | INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110033459-A1 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | PORTOLA PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| US-20080279845-A1 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | PORTOLA PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | disclosed |
| EP-1567519-B1 | CRYSTALLINE DERIVATIVES OF 2-(5-CHLOROTHIEN-2-YL)-N-((3S)-1((1S)-1-METHYL-2-MORPHOLIN-4-YL)-2-OXOETHYL)-2-OXOPYRROLIDIN-3-YL)ETHENSULFONAMIDE | GLAXO GROUP LTD (GB) | 2007-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009172-A1 | INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR | P2RY12, P2RY11, P2RY13 | F10 192/4885GAA 3195/4885KMT2A 4073/4885 |
| US-20080279845-A1 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | MPL, P2RY4, P2RY1 | F10 472/4885GAA 1706/4885KMT2A 3261/4885 |
| US-20110033459-A1 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | MPL, P2RY4, P2RY1 | F10 472/4885GAA 1706/4885KMT2A 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.